<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071928</url>
  </required_header>
  <id_info>
    <org_study_id>GU09-144</org_study_id>
    <nct_id>NCT01071928</nct_id>
  </id_info>
  <brief_title>Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma</brief_title>
  <official_title>A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety and activity of docetaxel + ASA404 as&#xD;
      second-line chemotherapy in patients with advanced urothelial carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
      21 Day Cycle Treatment Regimen:&#xD;
&#xD;
        -  Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1&#xD;
&#xD;
        -  ASA404 (given after Docetaxel) IV 1800 mg/m2 over approximately 20 minutes on Day 1&#xD;
&#xD;
      Treatment will continue until disease progression or intolerable treatment related adverse&#xD;
      effects.&#xD;
&#xD;
      Karnofsky performance status of ≥ 70% within 7 days prior to registration for protocol&#xD;
      therapy.&#xD;
&#xD;
      Life Expectancy: Not specified&#xD;
&#xD;
      Hematopoietic:&#xD;
&#xD;
        -  Hemoglobin (Hgb) &gt; 9 g/dL&#xD;
&#xD;
        -  Platelets &gt; 100 K/mm3&#xD;
&#xD;
        -  Absolute neutrophil count (ANC) &gt; 1.5 K/mm3&#xD;
&#xD;
        -  INR or Prothrombin Time (PT) &lt; 1.5 x ULN&#xD;
&#xD;
      Hepatic:&#xD;
&#xD;
        -  Bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
        -  Aspartate aminotransferase (AST, ALT) &lt; 2.5 x ULN&#xD;
&#xD;
      Renal:&#xD;
&#xD;
        -  Calculated creatinine clearance of &gt; 45 cc/min using the Cockcroft-Gault formula&#xD;
&#xD;
      Cardiovascular:&#xD;
&#xD;
        -  No congestive heart failure (NY Heart Association class III or IV)&#xD;
&#xD;
        -  No myocardial infarction within 12 months of study registration for protocol therapy or&#xD;
           with implanted cardiac pacemaker&#xD;
&#xD;
        -  No unstable or poorly controlled angina pectoris, including Prinzmetal variant angina&#xD;
           pectoris&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of efficacy of experimental treatment&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the best overall response rate (as measured by RECIST version 1.1) of docetaxel + ASA404 as second line therapy in patients with advanced urothelial carcinoma.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate progression-free survival in patients with advanced urothelial carcinoma</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate survival at 1 year from start of treatment in patients with advanced urothelial carcinoma treated with docetaxel + ASA404 as second line therapy</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of docetaxel and ASA404 combination, as measured by the NCI Common Toxicity Criteria version 3.0</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Docetaxel and ASA404 in Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1</description>
    <arm_group_label>Docetaxel and ASA404 in Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA404</intervention_name>
    <description>ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1</description>
    <arm_group_label>Docetaxel and ASA404 in Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological proof of transitional cell carcinoma (TCC) of the bladder,&#xD;
             urethra, ureter, or renal pelvis (urothelial carcinoma). Histology may be mixed, but&#xD;
             still requires a component of TCC.&#xD;
&#xD;
          -  Measurable disease according to RECIST (version 1.1) and obtained by imaging within 30&#xD;
             days prior to registration for protocol therapy. Note: Sites of measurable disease can&#xD;
             not be within a previously irradiated site.&#xD;
&#xD;
          -  Written informed consent and HIPAA authorization for release of personal health&#xD;
             information.&#xD;
&#xD;
          -  Age &gt; 18 years at the time of consent.&#xD;
&#xD;
          -  Must have received only one prior chemotherapy regimen, which must have included one&#xD;
             of the following chemotherapeutic agents: cisplatin, carboplatin, or gemcitabine.&#xD;
             Note: Prior chemotherapy may have been administered in the perioperative&#xD;
             (neoadjuvant/adjuvant) or advanced/metastatic setting. Patients may have received&#xD;
             prior treatment with paclitaxel.&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to use an effective method&#xD;
             of contraception (hormonal or barrier method of birth control; abstinence) from the&#xD;
             time consent is signed until 12 weeks after treatment discontinuation.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to registration for protocol therapy.&#xD;
&#xD;
          -  Females must not be breastfeeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No prior treatment with docetaxel.&#xD;
&#xD;
          -  No symptomatic brain metastases. Patients with neurological symptoms must undergo a&#xD;
             head CT scan or brain MRI to exclude brain metastasis. NOTE: Patients with treated&#xD;
             brain metastasis must be off steroids and have completed radiation at least 14 days&#xD;
             prior to registration for protocol therapy.&#xD;
&#xD;
          -  No prior malignancy is allowed except for adequately treated basal cell or squamous&#xD;
             cell skin cancer, in situ cervical cancer, Gleason &lt; grade 7 prostate cancers, or&#xD;
             other cancers for which the patient has been disease-free for at least 5 years&#xD;
&#xD;
          -  No treatment with any investigational agent or chemotherapeutic agent within 30 days&#xD;
             prior to registration for protocol therapy.&#xD;
&#xD;
          -  No radiotherapy within 14 days prior to registration for protocol therapy. Patients&#xD;
             must have recovered from all radiotherapy-related toxicities.&#xD;
&#xD;
          -  No major surgery within 30 days prior to registration for protocol therapy (major&#xD;
             surgery is defined by the use of general anesthesia).&#xD;
&#xD;
          -  No minor surgery 14 days prior to registration for protocol therapy. NOTE: Insertion&#xD;
             of a vascular access device is allowed.&#xD;
&#xD;
          -  No history of any medical condition resulting in ≥ CTC grade 2 dyspnea.&#xD;
&#xD;
          -  Patients without long QT syndrome&#xD;
&#xD;
          -  No history of labile hypertension or poor compliance with anti-hypertensive regimen&#xD;
             NOTE: No patients with systolic BP &gt;140 mm Hg and/or diastolic BP &gt; 90 mm Hg while on&#xD;
             medication for hypertension.&#xD;
&#xD;
          -  No presence of atrial tachyarrhythmia (e.g., atrial fibrillation, atrial flutter,&#xD;
             multifocal atrial tachycardia, supraventricular tachycardia) if not effectively&#xD;
             rate-controlled.&#xD;
&#xD;
          -  No history of a sustained ventricular tachycardia&#xD;
&#xD;
          -  No history of ventricular fibrillation or Torsades de Pointes&#xD;
&#xD;
          -  No right bundle branch block and left anterior or posterior hemiblock (bifascicular&#xD;
             block)&#xD;
&#xD;
          -  No bradycardia defined as heart rate &lt;50 beats per minute&#xD;
&#xD;
          -  No concomitant use of drugs with risk of causing Torsades de Pointes.&#xD;
&#xD;
          -  No concomitant use of drugs that are inducers and inhibitors of UGT1A9 and UGT2B7.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Galsky, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Cancer Research Network</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hoosier Cancer Research Network</investigator_affiliation>
    <investigator_full_name>Matthew Galsky</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Advanced Urothelial Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vadimezan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

